Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Best Practices for Sentinel Events: What Every Healthcare Organization Needs to Know

In any healthcare environment, patient safety is always top of mind. Each staff member is responsible for their own actions. Administrators are too, especially when those actions include reacting to a safety concern raised by an employee. To ensure that healthcare organizations have a high-reliability culture, the Joint Commission Center for Transforming Healthcare published a…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In any healthcare environment, patient safety is always top of mind. Each staff member is responsible for their own actions. Administrators are too, especially when those actions include reacting to a safety concern raised by an employee. To ensure that healthcare organizations have a high-reliability culture, the Joint Commission Center for Transforming Healthcare published a report, “Sentinel Event Alert 60: Developing a Reporting Culture: Learning from Close Calls and Hazardous Conditions.” 1 The Joint Commission issued this report to encourage a reporting culture where swift action is taken to remedy unsafe conditions.

What Is a Sentinel Event?

The Joint Commission’s mission is “to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value.2 The Joint Commission defines a sentinel event as an unanticipated event in a healthcare setting resulting in death or serious injury, physical or psychological, not related to natural causes or the patient’s illness. The Joint Commission identifies sentinel events in its accreditation policies to assist with root cause analysis and the development of new preventive measures. Accredited organizations are required to define sentinel events for their own care system and implement monitoring procedures and a process for root cause analysis.

Standards Must Be in Place to Respond to a Sentinel Event

Should a sentinel event occur, any accredited healthcare organization must have a process to respond. Causal factors need to be analyzed, focusing on the system holistically. An “action plan” should be put in place for potential improvements to decrease the chance of the event happening again. The Joint Commission encourages organizations to report any sentinel event, but it’s not required. The organization will have to create root cause analysis and an action plan within 45 days of the event. You can also consult with The Joint Commission on initiating the root cause analysis and action plan. If the event was due to a medical device defect, then an organization must report the incident to the Food and Drug Administration within 10 days.

There are benefits to reporting the event that can be of help to other organizations. A reported event is added to the database which other facilities have access to, providing vital information that could help to prevent a similar event from occurring at their organizations.

Sentinel Event Standards

Within the Performance Improvement and Leadership chapters of the accreditation manual, there are standards for the expectations regarding the internal identification and management of sentinel events.

With the organization’s definition of the sentinel event, it must include the specific events that would be reviewed under the Sentinel Event Policy. Following a sentinel event, the organization must begin its investigation by determining root cause analysis, then develop its plan and identify ways to reduce future risk. After the standards are implemented, they are closely monitored to ascertain their viability.

Reporting Is a Key Element of Sentinel Event Management

In order to manage sentinel events, your culture must be one that has adopted reporting. Only with reporting will you be able to truly understand the causes of a particular event and prevent similar events from happening again. The four Es of a Reporting Culture include:3

  1. Establish trust: there can be no culture of reporting without trust; leaders must show their continued commitment to safety and governance should support this as well.
  2. Encourage reporting: this means that reporting is accessible by all staff, easy to use, and delivers data analysis in a timely fashion. Encouragement also means that staff receives feedback so that they know the action is being taken when reports are made. The organization should also define the types of events that should be reported.
  3. Eliminate fear of punishment: ensure that your staff knows that there is no retaliation or punishment for reporting safety concerns. All staff, regardless of position, should be held to the same standards.
  4. Examine errors: refer to the data compiled and use it to identify the highest risk situations and take action. Data is also used to celebrate staff when they are successful. Data helps strengthen the safety program and the culture of reporting.

The Joint Commission also offers resources and support so you can continue to enhance a culture of reporting within your organization.4

https://www.alimed.com/_resources/common/userfiles/file/infographics/AliMed_ReportingCulture-Infographic.pdf

References

  1. https://www.jointcommission.org/
  2. https://www.jointcommission.org
  3. https://www.jointcommission.org/
  4. https://www.jointcommission.org/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512